Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 65 of 557 for:    Genetic AND family history

Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer (PERSONA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03920488
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : May 7, 2019
Sponsor:
Information provided by (Responsible Party):
European Institute of Oncology

Brief Summary:

For patients with triple negative breast cancer, implementation of genetic testing in decision making might impact both risk management for the patient and her family, but also, importantly, therapeutic management.

Identifying genetically predisposed subjects dictates risk-reducing strategies that may imply bilateral salpingo-oophorectomy and mastectomy or long term medical approaches. In the advanced setting, genetic testing can influence decision for medical therapy (e.g. use of platinum derivatives, poly-ADP ribose polymerase inhibitors (PARP inhibitors) in breast cancer patients with breast cancer susceptibility gene (BRCA) mutation.

The selection of patients for testing has long relied on the presence of a strong family history of breast and ovarian cancer. It is now clear that this criterion will result in substantial numbers of those with a BRCA mutation being missed.

Systematic large-scale genetic testing, simultaneously on germline and somatic tissues, is likely to improve decisional algorithms in patients with ovarian cancer. Feasibility of such approach in the clinical setting, in terms of a turnaround time compatible with clinical needs and sensitivity comparable if not superior to single-gene testing needs to be demonstrated before such diagnostic platforms can be routinely implemented in the diagnostic workflow. This is the scope of the present study.


Condition or disease
Triple Negative Breast Cancer

Detailed Description:

Systematic large-scale genetic testing, simultaneously on germline and somatic tissues, is likely to improve decisional algorithms in patients with triple negative breast cancers.

Feasibility of such approach in the clinical setting, in terms of a turnaround time compatible with clinical needs and sensitivity comparable if not superior to single-gene testing needs to be demonstrated before such diagnostc platforms can be routinely implemented in the diagnostic workflow.

Two platforms will be used during the course of the study. The Illumina TruSight Cancer Risk panel is a commercially validated targeted enrichment panel which targets 94 genes and 284 SNPs (Single Nucleotide Polymorphism) associated with a predisposition towards cancer.

The GermSom panel was developed at European Institute of Oncology (IEO) in collaboration with institutions within the Alleanza Contro il Cancro consortium and manufactured by Agilent Technologies. It includes 349 genes with an established function in the biology and/or pharmacological actionability of multiple solid tumors, including breast cancer. It includes all the genomic regions analysed in the Illumina Trusight panel, plus 32 additional regions associated with risk of multiple tumors.

Patients will receive detailed genetic characterization of their germline and their tumor. This will provide the best possible characterization of their risk of developing of a secondary malignancy and can be exploited to identify families at risk for hereditary cancer risk. Patients will also benefit from an increased likelihood of being treated with appropriate drugs and of receiving appropriate surgery.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 264 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluating the Feasibility of Next-Generation Sequencing - Based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer. The PERSONA-breast Trial
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Prevalence of mutations in breast cancer risk-associated genes [ Time Frame: 3 months ]
    Evaluate the prevalence of clinically relevant mutations in breast cancer risk-associated genes

  2. Genetic test turnaround time [ Time Frame: 6 months ]
    Evaluate feasibility of genetic testing for clinical decision making

  3. Percentage of informative specimens [ Time Frame: 3 months ]
    Percentage of patients with positive germline testing for target genes


Secondary Outcome Measures :
  1. Incidence of all other mutations [ Time Frame: 3 months ]
    Incidence of all other mutations

  2. disease-free survival [ Time Frame: 10 years ]
    collection of disease associated events during follow-up

  3. overall survival [ Time Frame: 10 years ]
    collection of death events during follow-up


Biospecimen Retention:   Samples With DNA
whole blood specimens


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with triple-negative breast cancer, stage I-III, cadidates for surgery
Criteria

Inclusion Criteria:

  1. age between 18 and 60 years
  2. has signed informed consent
  3. histologically confirmed triple negative breast cancer (ER (Estrogen Receptors) < 1%, PgR (Progesterone Receptors) < 1%, HER2/neu negative (IHC 0, 1+ or 2+ FISH negative).
  4. Stage I-III
  5. Able to undergo surgery (primary or post-neoadjuvant)
  6. Availability of surgical/bioptic material within 6 months from enrolment

Exclusion Criteria:

  • unable or unwilling to receive genetic counselling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03920488


Contacts
Layout table for location contacts
Contact: Viviana E Galimberti, MD +390257489717 viviana.galimberti@ieo.it

Locations
Layout table for location information
Italy
Istituto Europeo di Oncologia Recruiting
Milan, Italy
Contact: Viviana E Galimberti, MD         
Sponsors and Collaborators
European Institute of Oncology
Investigators
Layout table for investigator information
Principal Investigator: Viviana E Galimberti, MD IEO

Layout table for additonal information
Responsible Party: European Institute of Oncology
ClinicalTrials.gov Identifier: NCT03920488     History of Changes
Other Study ID Numbers: IEO 0761/
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by European Institute of Oncology:
genetic testing
breast cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases